SOMERSET, N.J. and LA JOLLA, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, today announced that Triphase will obtain worldwide rights to further develop Catalent`s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent`s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag(TM) technology platform.
Catalent will receive an upfront payment and has the potential to earn additional development and commercial milestone payments, plus a royalty on product sales. Triphase will also contract with Catalent for development, manufacturing and analytical services to support a fast path to clinic.
CD22-4AP is a novel, site-specific ADC, targeting CD22, a B-cell restricted sialoglycoprotein that is an important modulator of B-cell signaling and survival, which is expressed on 90% of B-cell malignancies. CD22 is a clinically validated ADC target with potential in Non-Hodgkin`s Lymphoma (NHL) and Acute Lymphoid Leukemia (ALL). Catalent`s ADC, CD22-4AP, is a site-specific modified humanized antibody conjugated to a toxin payload using Catalent`s proprietary Hydrazino-Pictet-Spengler (HIPS(TM)) chemistry and proprietary 4AP linker.
Pre-clinical data has shown that this optimization of payload placement and linker composition, combined with the stability afforded by HIPS chemistry, leads to better tolerability and expanded therapeutic index.
Dr. Mohit Trikha, Chief Scientific Officer, Executive Vice President and Head of R&D at Triphase, commented, "Given our deep experience in investigating potential treatment for blood cancers and oncology clinical drug development, it is a logical progression for us to explore other approaches for other hematologic tumors. We believe in the potential of Catalent`s SMARTag technology and look forward to advancing CD22-4AP to clinical proof of concept studies."
"Triphase has demonstrated expertise and a track record in advancing pre-clinical oncology candidates to clinical proof of concept," added Mike Riley, Catalent Biologics` Vice President & General Manager. "We look forward to leveraging Triphase`s expertise in combination with our proprietary SMARTag technology and supporting infrastructure to bring this potentially transformational treatment to patients."
About the SMARTag(TM) Technology
The proprietary SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. The technology employs natural post-translational modifications found in human cells to create one or more aldehyde tags at designated sites on protein molecules. These chemical "handles`` are then stably conjugated to payloads (e.g., cytotoxic or effector) to prevent their systemic release. The SMARTag platform provides precise payload positioning, stable, site-specific conjugation and defined stoichiometry of drug-protein ratios. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates. Catalent acquired Redwood Bioscience in 2014.
About Triphase Accelerator
Triphase Accelerator is a private drug development company with a primary focus on oncology and with operations in Toronto and San Diego. Triphase Accelerator is dedicated to advancing novel compounds through Phase 2 proof-of-concept clinical studies using a unique, science-based, high-quality model that is faster and more cost-effective than traditional pharmaceutical and biotech industry drug development approaches. Triphase Accelerator was spun out of the Ontario Institute for Cancer Research (OICR), with support from the Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation and MaRS. It has a strategic relationship with Celgene for oncology-focused drug development opportunities. For more information, visit www.triphaseco.com or LinkedIn.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,200 people, including over 1,400 scientists, at over 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.(TM)
Chris Halling Catalent Pharma Solutions +44 (0) 7580 41073 Chris.firstname.lastname@example.org
Richard Kerns NEPR +44 (0) 161 728 5880 email@example.com
Jules Abraham JQA Partners, Inc. +1 917-885-7378 firstname.lastname@example.org
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Triphase Accelerator via GlobeNewswire